Illumina to preview newest innovations in NGS and multiomic technologies at the American Society of Human Genetics Annual Meeting
Illumina announced upcoming presentations of key innovations at the American Society of Human Genetics Annual Meeting. The company will showcase its new constellation mapped read technology, designed to streamline whole-genome workflows and deliver more comprehensive genomic insights. Early access will begin in first half 2025.
The company will also present updates on Illumina Protein Prep, a proteomics solution launching in early 2025 capable of identifying 9000 unique human proteins, and PIPseq V, a single-cell analysis solution. Additionally, Illumina will release 25B 100-cycle and 200-cycle kits for the NovaSeq X Series by year-end.
Illumina ha annunciato prossime presentazioni di innovazioni chiave durante l'Annual Meeting della American Society of Human Genetics. L'azienda metterà in mostra la sua nuova tecnologia di lettura mappata a costellazione, progettata per semplificare i flussi di lavoro dell'intero genoma e fornire informazioni genomiche più complete. L'accesso anticipato inizierà nella prima metà del 2025.
L'azienda presenterà anche aggiornamenti su Illumina Protein Prep, una soluzione di proteomica che verrà lanciata all'inizio del 2025 e capace di identificare 9000 proteine umane uniche, e PIPseq V, una soluzione di analisi a singola cellula. Inoltre, Illumina rilascerà kit da 25B 100 cicli e 200 cicli per la serie NovaSeq X entro la fine dell'anno.
Illumina anunció próximas presentaciones de innovaciones clave en la Reunión Anual de la Sociedad Americana de Genética Humana. La empresa mostrará su nueva tecnología de lectura mapeada en constelación, diseñada para optimizar los flujos de trabajo de todo el genoma y ofrecer información genómica más completa. El acceso anticipado comenzará en la primera mitad de 2025.
La empresa también presentará actualizaciones sobre Illumina Protein Prep, una solución de proteómica que se lanzará a principios de 2025 capaz de identificar 9000 proteínas humanas únicas, y PIPseq V, una solución de análisis de célula única. Además, Illumina lanzará kits de 25B de 100 ciclos y 200 ciclos para la serie NovaSeq X antes de fin de año.
일루미나는 미국 인체 유전학회 연례 회의에서 주요 혁신을 발표할 예정이라고 알렸습니다. 이 회사는 전체 유전체 워크플로우를 간소화하고 보다 포괄적인 유전적 통찰력을 제공하도록 설계된 별자리 매핑 리드 기술을 선보일 것입니다. 조기 액세스는 2025년 상반기에 시작됩니다.
이 회사는 또한 2025년 초에 출시될 9000개의 고유한 인간 단백질을 식별할 수 있는 단백질체 솔루션인 Illumina Protein Prep와 단일 세포 분석 솔루션인 PIPseq V에 대한 업데이트를 발표할 것입니다. 또한, Illumina는 연말까지 NovaSeq X 시리즈용 25B 100 사이클 및 200 사이클 키트를 출시할 예정입니다.
Illumina a annoncé des présentations à venir d'innovations clés lors de la réunion annuelle de la Société Américaine de Génétique Humaine. L'entreprise présentera sa nouvelle technologie de lecture cartographiée en constellation, conçue pour rationaliser les flux de travail du génome entier et fournir des informations génomiques plus complètes. L'accès anticipé débutera au cours de la première moitié de 2025.
La société présentera également des mises à jour sur Illumina Protein Prep, une solution de protéomique qui sera lancée au début de 2025 et capable d'identifier 9000 protéines humaines uniques, ainsi que sur PIPseq V, une solution d'analyse unicellulaire. De plus, Illumina lancera des kits de 25B de 100 cycles et 200 cycles pour la série NovaSeq X d'ici la fin de l'année.
Illumina kündigte bevorstehende Präsentationen wichtiger Innovationen auf dem Jahrestreffen der American Society of Human Genetics an. Das Unternehmen wird seine neue konstellationsgemappte Lesetechnologie vorstellen, die entwickelt wurde, um die gesamte Genom-Workflows zu optimieren und umfassendere genomische Einblicke zu liefern. Der frühzeitige Zugriff beginnt in der ersten Hälfte von 2025.
Das Unternehmen wird auch Updates zu Illumina Protein Prep präsentieren, einer Proteomik-Lösung, die Anfang 2025 auf den Markt kommt und 9000 einzigartige menschliche Proteine identifizieren kann, sowie zu PIPseq V, einer Lösung zur Einzelzellanalyse. Zusätzlich wird Illumina bis zum Ende des Jahres 25B 100-Zyklen- und 200-Zyklen-Kits für die NovaSeq X-Serie herausbringen.
- New constellation mapped read technology eliminates traditional library prep and streamlines workflows
- Protein Prep solution capable of identifying over 9000 human proteins
- 25B 100-cycle and 200-cycle kits for NovaSeq X Series launching by year-end
- None.
Insights
The announcement of Illumina's constellation mapped read technology represents a significant technical advancement in genome sequencing. The key innovations include streamlined whole-genome workflows, elimination of library prep requirements and integration with XLEAP-SBS chemistry. This could potentially reduce operational costs and improve efficiency for clinical labs.
The technology's ability to resolve pseudogenes and provide ultra-long phased data addresses current limitations in genome sequencing. While promising, the early 2025 access timeline suggests revenue impact won't be immediate. The expansion to 9000 unique human proteins in the Protein Prep solution and the introduction of 25B 100-cycle and 200-cycle kits for NovaSeq X Series demonstrate a strategic focus on comprehensive genomic analysis capabilities.
The development of Illumina Protein Prep marks a strategic expansion into proteomics, enabling researchers to identify over 6000 human proteins initially, scaling to 9000 at launch. This multiomics approach on a single platform could significantly impact cancer research and biomarker discovery, as evidenced by TGen's pilot study.
The integration of proteomics with genomics creates a more complete picture of biological processes, potentially accelerating drug development and disease research. The compatibility with NovaSeq X and NovaSeq 6000 Systems positions Illumina to capture a larger share of the growing proteomics market, estimated at
- New, groundbreaking technology delivers Illumina's most comprehensive genome yet; early results from Broad Clinical Labs demonstrate a highly simplified workflow, ultra-long phasing, high-resolution insights into complex genomic variation, and enhanced long-range information
- Illumina and customers will also showcase new details on complete proteomics solution and latest data on Fluent single-cell technology
First-of-its-kind technology streamlines whole-genome workflows, expands genomic insights
In a mainstage presentation on November 6, Steve Barnard, PhD, chief technology officer, will reveal new details on the company's constellation mapped read technology, originally announced in the company's August 2024 strategy update as the "comprehensive genome." Currently under development, this novel technology is designed to streamline whole-genome workflows and eliminate traditional library prep.
Additionally, constellation mapped read technology will deliver Illumina's most comprehensive whole genome yet, adding long-range information to Illumina's proven, highly accurate XLEAP-SBS™ chemistry. The expanded insights from this proprietary technology will resolve challenging genic regions, such as pseudogenes, while generating ultra-long phased data and providing a high-resolution view of complex structural variation.
"These are unprecedented, breakthrough technologies that will power our future comprehensive whole-genome solutions," Barnard said. "We believe this solution could be the de facto genome of the future, offering expanded information and simplicity for labs."
Barnard will be joined on stage by Niall Lennon, PhD, chair and chief scientific officer of Broad Clinical Labs, who will present early data on the flexibility and capabilities of the technology.
The first product based on constellation mapped read technology is set to begin early access in the first half of 2025.
Illumina Protein Prep: A complete NGS-based proteomics solution
On November 7, Illumina will present updates on its proteomics solution, Illumina Protein Prep, which delivers sample-to-analysis protein discovery. The solution is an outcome of Illumina's partnership with Standard BioTools (formerly SomaLogic), announced in 2022.
Proteomics enables the observation of direct cellular function to gain insights on protein-driven disease traits, and the inclusion of proteomics in Illumina's NGS portfolio provides visibility into the entire biological process. The presentation will highlight the early access solution's ability to identify and quantify more than 6000 human proteins and its readout compatibility with NovaSeq™ X and NovaSeq 6000 Systems to enable multiomics on a single platform—a key differentiator from existing proteomics methodologies.
Kamel Lahouel, PhD, assistant professor in the Early Detection and Prevention Division at The Translational Genomics Research Institute (TGen), part of City of Hope, will present on a new pilot study using Illumina Protein Prep to investigate the potential of circulating protein concentrations as biomarkers for cancer detection. TGen is part of an early access, limited release program for the solution with select customers.
When it launches in early 2025, Illumina Protein Prep will feature 9000 unique human proteins.
Leading single-cell technology: Fluent PIPseq™ V
On November 7, Illumina will showcase PIPseq V, a single-cell analysis solution currently on the market from Fluent BioSciences, an Illumina company. In a collaborative talk, experts will discuss how PIPseq V enables researchers to delve deeper into the complexities of cell biology with a scalable, accessible solution. Presenters will share early access data and insights from a large study on more than 1 million neuronal single cells using PIPseq V.
Additional updates
Barnard's presentation on November 6 will also cover the latest updates on 25B 100-cycle and 200-cycle kits for the NovaSeq X Series, which will be available by end of year. The kits will be a key enabler of multiomics, allowing customers to perform single-cell, proteomics, and other applications at scale.
"We look forward to expanding on these innovations with our customers and peers at ASHG," Barnard said. "We also look forward to sharing our latest instruments, the MiSeq™ i100 Series, with our fellow NGS enthusiasts at our booth."
Illumina's new MiSeq i100 Series will be on display at booth 503 during the meeting, and Illumina will be presenting scientific findings in five poster presentations and abstracts.
Use of forward-looking statements
This release may contain forward-looking statements that involve risks and uncertainties. Among the important factors to which our business is subject that could cause actual results to differ materially from those in any forward-looking statements are: (i) challenges inherent in developing and launching new products and services, including modifying and scaling manufacturing operations, and reliance on third-party suppliers for critical components; (ii) our ability to manufacture robust instrumentation and consumables; and (iii) the acceptance by customers of our newly launched products, which may or may not meet our and their expectations, together with other factors detailed in our filings with the Securities and Exchange Commission, including our most recent filings on Forms 10-K and 10-Q, or in information disclosed in public conference calls, the date and time of which are released beforehand. We undertake no obligation, and do not intend, to update these forward-looking statements, to review or confirm analysts' expectations, or to provide interim reports or updates on the progress of the current quarter.
About Illumina
Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as a global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. To learn more, visit illumina.com and connect with us on X, Facebook, LinkedIn, Instagram, TikTok, and YouTube.
Contacts
Investors:
Salli Schwartz
858-291-6421
IR@illumina.com
Media:
Christine Douglass
PR@illumina.com
View original content:https://www.prnewswire.com/news-releases/illumina-to-preview-newest-innovations-in-ngs-and-multiomic-technologies-at-the-american-society-of-human-genetics-annual-meeting-302292671.html
SOURCE Illumina, Inc.
FAQ
When will Illumina's constellation mapped read technology be available for early access?
How many human proteins can Illumina Protein Prep identify and quantify?
What new kits is ILMN releasing for the NovaSeq X Series?
